Who are alpha-blocker or 5-ARI withdrawal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Visine® for Contacts®, brompheniramine + phenylephrine, Xylocaine with Epinephrine, Naproxen Sodium & Pseudoephedrine HCl, Continuous infusion of Norepinephrine, Buffered Articaine Hydrochloride + Epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha-blocker-or-5-ari-withdrawal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

alpha-blocker or 5-ARI withdrawal — Competitive Intelligence Brief

alpha-blocker or 5-ARI withdrawal (alpha-blocker or 5-ARI withdrawal) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpha-blocker. Area: Urology.

phase 3 alpha-blocker alpha-1 adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

alpha-blocker or 5-ARI withdrawal (alpha-blocker or 5-ARI withdrawal) — Gangnam Severance Hospital. Alpha-blockers block alpha-1 adrenergic receptors, causing smooth muscle relaxation and vasodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
alpha-blocker or 5-ARI withdrawal TARGET	alpha-blocker or 5-ARI withdrawal	Gangnam Severance Hospital	phase 3	alpha-blocker	alpha-1 adrenergic receptor
Visine® for Contacts®	Visine® for Contacts®	Merck Sharp & Dohme LLC	marketed	Ophthalmic decongestant	Alpha-1 adrenergic receptor
brompheniramine + phenylephrine	brompheniramine + phenylephrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (phenylephrine)
Xylocaine with Epinephrine	Xylocaine with Epinephrine	Vrije Universiteit Brussel	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors
Naproxen Sodium & Pseudoephedrine HCl	Naproxen Sodium & Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (naproxen); alpha-1 adrenergic receptor (pseudoephedrine)
Continuous infusion of Norepinephrine	Continuous infusion of Norepinephrine	Hassan II University	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alpha-blocker class)

Gangnam Severance Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). alpha-blocker or 5-ARI withdrawal — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha-blocker-or-5-ari-withdrawal. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab